What is "zalutumumab"

n. A human monoclonal antibody designed for the treatment of cancer of the head and neck.

Zalutumumab (proposed trade name HuMax-EGFr) is a fully human IgG1 monoclonal antibody (mAb) directed towards the epidermal growth factor receptor (EGFr). It is a product developed by Genmab in Utrecht, the Netherlands. Specifically, zalutumumab is designed for the treatment of squamous cell carcinoma of the head and neck ( SCCHN), a type of cancer.

The current treatment for SCCHN includes tyrosine kinase inhibitors and human monoclonal antibodies.